Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
NANJING, China, July 29, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2013 on Tuesday, August 13, 2013, before the market opens in the United States. Simcere’s management will host an earnings conference call on the same day at 8 a.m. ET (Tuesday, August 13 at 8 p.m.Beijing/Hong Kong time).
To access the conference call, please dial:
International toll: | +65.6723.9381 |
United States toll-free: | +1.866.519.4004 |
United States toll: | +1.845.675.0437 |
China Domestic toll: | 800.819.0121 |
China Domestic mobile toll: | 400.620.8038 |
Hong Kong toll: | +852.2475.0994 |
Please ask to be connected to Q2 2013 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 23263347.
Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the “Investor Relations” section of the company’s web site at www.simcere.com.
Following the earnings conference call, an archive of the call will be available by dialing:
United States toll-free: | +1. 855.452.5696 |
United States toll: | +1. 646.254.3697 |
The passcode for replay participants is 23263347. The telephone replay also will be archived on the “Investor Relations” section of the company’s website for seven days following the earnings announcement.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.
Investor and Media Contacts:
Email: ir@simcere.com
In Nanjing: Tel: 86-25-8556-6666*8857
In Beijing: Brunswick Group Tel: 86-10-5960-8600 | In the United States: Cindy Zheng Brunswick Group Tel: 1-212-333-3810
|
SOURCE Simcere Pharmaceutical Group
Help employers find you! Check out all the jobs and post your resume.
